180 related articles for article (PubMed ID: 36286729)
1. [Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience].
Zherebtsova VA; Vorobyev VI; Gemdzhian EG; Ulyanova MA; Chernikov MV; Ivanova VL; Vinogradova OY; Ptushkin VV
Ter Arkh; 2021 Jul; 93(7):785-792. PubMed ID: 36286729
[TBL] [Abstract][Full Text] [Related]
2. Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Mele A; Prete E; De Risi C; Citiso S; Greco G; Falcone AP; Sanpaolo G; Mele G; Giannotta A; Vergine C; Reddiconto G; Palazzo G; Sabatelli S; Germano C; Miccolis R; Curci P; Palumbo G; Offidani M; Rizzi R; Cascavilla N; Pastore D; Di Renzo N; Mazza P; Tarantini G; Guarini A; Capalbo S; Specchia G; Greco A; De Francesco R; Sibilla S; Tonialini L; Morciano MR; Pavone V
Ann Hematol; 2021 Feb; 100(2):429-436. PubMed ID: 33161453
[TBL] [Abstract][Full Text] [Related]
3. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
4. A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma.
Rocchi S; Tacchetti P; Pantani L; Mancuso K; Rizzello I; di Giovanni Bezzi C; Scalese M; Dozza L; Marzocchi G; Martello M; Barilà G; Antonioli E; Staderini M; Buda G; Petrini M; Cea M; Quaresima M; Furlan A; Bonalumi A; Cavo M; Zamagni E
Hematol Oncol; 2021 Feb; 39(1):41-50. PubMed ID: 33085797
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
6. Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study.
Dimopoulos M; Wang M; Maisnar V; Minarik J; Bensinger W; Mateos MV; Obreja M; Blaedel J; Moreau P
J Hematol Oncol; 2018 Apr; 11(1):49. PubMed ID: 29615082
[TBL] [Abstract][Full Text] [Related]
7. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Siegel DS; Dimopoulos MA; Ludwig H; Facon T; Goldschmidt H; Jakubowiak A; San-Miguel J; Obreja M; Blaedel J; Stewart AK
J Clin Oncol; 2018 Mar; 36(8):728-734. PubMed ID: 29341834
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.
Mateos MV; Goldschmidt H; San-Miguel J; Mikhael J; DeCosta L; Zhou L; Obreja M; Blaedel J; Szabo Z; Leleu X
Hematol Oncol; 2018 Apr; 36(2):463-470. PubMed ID: 29446103
[TBL] [Abstract][Full Text] [Related]
10. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
Lee JH; Park Y; Kang KW; Lee JJ; Lee HS; Eom HS; Do YR; Kim JS; Yoon SS; Shin DY; Koh Y; Kim KH; Lee WS; Jo JC; Lee YJ; Lee JY; Kim DS; Shim H; Chang MH; Kim SH; Min CK;
Ann Hematol; 2021 Aug; 100(8):2051-2059. PubMed ID: 33447888
[TBL] [Abstract][Full Text] [Related]
11. A Clinical and Correlative Study of Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd) for Lenalidomide Refractory Multiple Myeloma in First Relapse.
Bhutani M; Foureau DM; Robinson M; Guo F; Fesenkova K; Atrash S; Paul B; Varga C; Friend R; Pineda-Roman M; Rigby K; Symanowski JT; Norek S; Tucker MR; Druhan LJ; Voorhees PM; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):535-544.e1. PubMed ID: 37127471
[TBL] [Abstract][Full Text] [Related]
12. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A
Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175
[TBL] [Abstract][Full Text] [Related]
13. Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Martino EA; Conticello C; Zamagni E; Pavone V; Palmieri S; Musso M; Tacchetti P; Mele A; Catalano L; Vigna E; Bruzzese A; Mendicino F; Botta C; Vincelli ID; Farina G; Barone M; Cangialosi C; Mancuso K; Rizziello I; Rocchi S; Falcone AP; Mele G; Reddiconto G; Garibaldi B; Iaccino E; Tripepi G; Gamberi B; Di Raimondo F; Musto P; Neri A; Cavo M; Morabito F; Gentile M
Hematol Oncol; 2022 Dec; 40(5):1009-1019. PubMed ID: 35638723
[TBL] [Abstract][Full Text] [Related]
14. Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.
O'Donnell E; Mo C; Yee AJ; Nadeem O; Laubach J; Rosenblatt J; Munshi N; Midha S; Cirstea D; Chrysafi P; Horick N; Richardson PG; Raje N
Lancet Haematol; 2024 Jun; 11(6):e415-e424. PubMed ID: 38677302
[TBL] [Abstract][Full Text] [Related]
15. Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Morabito F; Zamagni E; Conticello C; Pavone V; Palmieri S; Bringhen S; Galli M; Mangiacavalli S; Derudas D; Rossi E; Ria R; Catalano L; Tacchetti P; Mele G; Donatella Vincelli I; Antonia Martino E; Vigna E; Botta C; Bruzzese A; Mele A; Pantani L; Rocchi S; Garibaldi B; Cascavilla N; Ballanti S; Tripepi G; Frigeri F; Pia Falcone A; Cangialosi C; Reddiconto G; Farina G; Barone M; Rizzello I; Musto P; De Stefano V; Musso M; Teresa Petrucci M; Offidani M; Neri A; Di Renzo N; Di Raimondo F; Boccadoro M; Cavo M; Gentile M
Eur J Haematol; 2022 Mar; 108(3):178-189. PubMed ID: 34716957
[TBL] [Abstract][Full Text] [Related]
16. Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.
Yoroidaka T; Yamashita T; Murata R; Yoshihara K; Yoshihara S; Ueda M; Nakao S; Matsue K; Takamatsu H
Anticancer Res; 2023 Jan; 43(1):157-165. PubMed ID: 36585165
[TBL] [Abstract][Full Text] [Related]
17. Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data.
Campioni M; Agirrezabal I; Hajek R; Minarik J; Pour L; Spicka I; Gonzalez-McQuire S; Jandova P; Maisnar V
Eur J Health Econ; 2020 Mar; 21(2):219-233. PubMed ID: 31673898
[TBL] [Abstract][Full Text] [Related]
18. Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
Stewart AK; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Buchanan J; Cocks K; Yang X; Xing B; Zojwalla N; Tonda M; Moreau P; Palumbo A
J Clin Oncol; 2016 Nov; 34(32):3921-3930. PubMed ID: 27601539
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network.
Antonioli E; Pilerci S; Attucci I; Buda G; Gozzetti A; Candi V; Simonetti F; Giudice MLD; Ciofini S; Staderini M; Grammatico S; Buzzichelli A; Messeri M; Bocchia M; Galimberti S; Vannucchi AM
Front Oncol; 2023; 13():1162990. PubMed ID: 37182182
[TBL] [Abstract][Full Text] [Related]
20. A phase 1b study of once-weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Alsina M; Landgren O; Raje N; Niesvizky R; Bensinger WI; Berdeja JG; Kovacsovics T; Vesole DH; Fang B; Kimball AS; Siegel DS
Am J Hematol; 2021 Feb; 96(2):226-233. PubMed ID: 33125764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
